The FDA also approved the MC4R agonist-Setmelanotide for use in individuals with severe obesity due to either POMC, PCSK1 (proprotein convertase subtilisin/kexin type 1), or LEPR (leptin receptor) deficiency at the end of 2020 (85). The gene discussed is POMC; the disease is obesity disorder.